Skip to main content

Vomiting

9
Pipeline Programs
7
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
6
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 14 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Monarch Therapeutics
Monarch TherapeuticsPA - Philadelphia
1 program
1
TopiramatePhase 41 trial
Active Trials
NCT00286988Terminated12Est. Jun 2007
ViiV Healthcare
ViiV HealthcareNC - Durham
4 programs
2
1
CasopitantPhase 31 trial
CasopitantPhase 11 trial
GW679769Phase 11 trial
HEC or MECN/A1 trial
Active Trials
NCT01366599Completed12,058Est. Jul 2009
NCT00358813Completed18Est. Aug 2008
NCT00359177Completed24Est. Oct 2006
+1 more trials
MSD
MSDIreland - Ballydine
3 programs
2
RotaTeq™ - Rotavirus Vaccine, Live, Oral, PentavalentPhase 3Vaccine
aprepitantPhase 3
Functional Living Index - EmesisN/A
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
2
RotaTeq™ - Rotavirus Vaccine, Live, Oral, PentavalentPhase 3Vaccine
aprepitantPhase 3
Functional Living Index - EmesisN/A
Astellas
AstellasChina - Shenyang
1 program
1
RamosetronPhase 31 trial
Active Trials
NCT00272285Completed287Est. Mar 2008
GSK
GSKLONDON, United Kingdom
3 programs
HEC or MECN/A
CasopitantPHASE_1
GW679769PHASE_1
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Functional Living Index - EmesisN/A1 trial
Active Trials
NCT00696280Completed106Est. Nov 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Monarch TherapeuticsTopiramate
ViiV HealthcareCasopitant
AstellasRamosetron
ViiV HealthcareCasopitant
ViiV HealthcareGW679769
ViiV HealthcareHEC or MEC
Merck & Co.Functional Living Index - Emesis

Clinical Trials (7)

Total enrollment: 14,345 patients across 7 trials

NCT00286988Monarch TherapeuticsTopiramate

Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children

Start: Mar 2006Est. completion: Jun 200712 patients
Phase 4Terminated
NCT00366834ViiV HealthcareCasopitant

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

Start: Jul 2006Est. completion: Oct 20091,840 patients
Phase 3Completed
NCT00272285AstellasRamosetron

A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea

Start: Jan 2006Est. completion: Mar 2008287 patients
Phase 3Completed
NCT00358813ViiV HealthcareCasopitant

Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment

Start: Sep 2006Est. completion: Aug 200818 patients
Phase 1Completed
NCT00359177ViiV HealthcareGW679769

Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment

Start: Dec 2005Est. completion: Oct 200624 patients
Phase 1Completed
NCT01366599ViiV HealthcareHEC or MEC

CV Events in Emetogenic Chemotherapy

Start: May 2009Est. completion: Jul 200912,058 patients
N/ACompleted
NCT00696280Merck & Co.Functional Living Index - Emesis

Observational Study of Delayed Nausea and Vomiting

Start: Nov 2006Est. completion: Nov 2009106 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.